Solesis Announces Investment from Altaris Capital Partners digitalfacility.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from digitalfacility.com Daily Mail and Mail on Sunday newspapers.
April 15, 2021
TELFORD, Pa. April 15, 2021 Solesis Inc. (“Solesis” or the “Company”), the healthcare subsidiary of Compagnie Generale des Etablissements Michelin SCA (“Michelin”), announced today that Altaris Capital Partners, LLC (collectively with its affiliates, “Altaris”) has entered into an agreement to acquire a 51% stake in Solesis from Michelin. Michelin will maintain a 49% interest and will formalize a research and development initiative with Solesis to develop advanced polymers for life sciences and medical technology applications.
Solesis is an innovative provider of biomaterials, tools and services for the life science and medical technology industries. Solesis operates through two primary business divisions, Secant Group and Charter Medical. The Secant Group, which includes SanaVita Medical, is a supplier of biomaterials and implantable textile structures that enable repair, recovery and regeneration of human tissue, as well as technical materials f
Perrigo to sell prescription drug business for $1 55B hollandsentinel.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from hollandsentinel.com Daily Mail and Mail on Sunday newspapers.
Perrigo sells prescription drugs division
file photo
and last updated 2021-03-02 10:34:10-05
DUBLIN â Altaris Capital Partners announced Tuesday that itâll acquire the prescription pharmaceuticals division of Perrigo for $1.55 billion.
The acquisition is expected to close sometime in calendar year 2021, subject to customary closing conditions, a news release said.
After the transaction closes, Perrigo Rx, which has locations in Allegan, Holland and Grand Rapids, will be renamed and headquartered in downtown Grand Rapids.
âI am thrilled that we are working with Altaris to establish Perrigoâs Rx business as an independent company,â said Sharon Kochan, president of Rx. âThis is a very important and exciting milestone that will enable us to focus on executing our ambitious plans and growth strategy. Altarisâ health care specialization and experience with similar business separations will bring unique, fresh and relevant perspectives as we embark o
Share this article
Share this article
DUBLIN, March 1, 2021 /PRNewswire/ Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of
Consumer Self-Care Products, announced today that it has reached a definitive agreement to sell its Generic Rx Pharmaceuticals business to Altaris Capital Partners, LLC for total consideration of $1.55 billion, including $1.5 billion in cash, subject to customary adjustments. As part of the consideration, Altaris will also assume more than $50 million in potential R&D milestone payments and contingent purchase obligations with third-party Rx partners.
Perrigo CEO and President Murray S. Kessler commented, The sale of our Generic Rx business is the most impactful step in Perrigo s transformation plan. This transaction establishes Perrigo as a pure-play global consumer self-care company with industry leading fundamentals. Perrigo Consumer Self-Care will have a focused portfolio with over $4 billion in revenues focused on the growing tre